Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.

Dunn LJ, Kerwin EM, DeAngelis K, Darken P, Gillen M, Dorinsky P.

Pulm Pharmacol Ther. 2020 Feb;60:101873. doi: 10.1016/j.pupt.2019.101873. Epub 2019 Dec 10.

2.

Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.

Ruiz S, Zhao H, Chandakkar P, Papoin J, Choi H, Nomura-Kitabayashi A, Patel R, Gillen M, Diao L, Chatterjee PK, He M, Al-Abed Y, Wang P, Metz CN, Oh SP, Blanc L, Campagne F, Marambaud P.

J Clin Invest. 2020 Feb 3;130(2):942-957. doi: 10.1172/JCI127425.

3.
4.

Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers.

Shen Z, Lee CA, Wallach K, Valdez S, Wilson DM, Kerr B, Gillen M.

Clin Pharmacol Drug Dev. 2019 Jul;8(5):657-663. doi: 10.1002/cpdd.662. Epub 2019 Feb 13.

PMID:
30758919
5.

Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.

Shen Z, Lee CA, Valdez S, Yang X, Wilson DM, Flanagan T, Gillen M.

Clin Pharmacol Drug Dev. 2019 Jul;8(5):647-656. doi: 10.1002/cpdd.663. Epub 2019 Feb 12.

PMID:
30748125
6.

A review of research linking body image and sexual well-being.

Gillen MM, Markey CH.

Body Image. 2019 Dec;31:294-301. doi: 10.1016/j.bodyim.2018.12.004. Epub 2018 Dec 21.

PMID:
30584001
7.

Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans.

Shah V, Yang C, Shen Z, Kerr BM, Tieu K, Wilson DM, Hall J, Gillen M, Lee CA.

Xenobiotica. 2019 Jul;49(7):811-822. doi: 10.1080/00498254.2018.1504257. Epub 2018 Sep 12.

PMID:
30117757
8.

Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler.

Gillen M, Forte P, Svensson JO, Lamarca R, Burke J, Rask K, Larsdotter Nilsson U, Eckerwall G.

Pulm Pharmacol Ther. 2018 Oct;52:7-17. doi: 10.1016/j.pupt.2018.08.001. Epub 2018 Aug 2.

9.

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.

Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C.

Drug Des Devel Ther. 2018 Jun 20;12:1799-1807. doi: 10.2147/DDDT.S152659. eCollection 2018.

10.

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.

Smith WB, Hall J, Berg JK, Kazimir M, Yamamoto A, Walker S, Lee CA, Shen Z, Wilson DM, Zhou D, Gillen M, Marbury TC.

Clin Drug Investig. 2018 Aug;38(8):703-713. doi: 10.1007/s40261-018-0652-2.

11.

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.

Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, Ito Y, Hall J.

Rheumatology (Oxford). 2018 Sep 1;57(9):1602-1610. doi: 10.1093/rheumatology/key100.

12.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M.

J Clin Pharmacol. 2018 Sep;58(9):1214-1222. doi: 10.1002/jcph.1119. Epub 2018 May 7.

13.

Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease.

Fakih F, Spangenthal S, Sigal B, Darken P, Maes A, Siddiqui S, Gillen M, Reisner C, Martin UJ.

Respir Med. 2018 May;138:74-80. doi: 10.1016/j.rmed.2018.03.033. Epub 2018 Mar 30.

14.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.

Hall J, Gillen M, Yang X, Shen Z.

Clin Pharmacol Drug Dev. 2019 Feb;8(2):179-187. doi: 10.1002/cpdd.463. Epub 2018 Apr 24.

15.

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.

Fleischmann R, Winkle P, Hall J, Valdez S, Liu S, Yan X, Hicks L, Lee C, Miner JN, Gillen M, Hernandez-Illas M.

RMD Open. 2018 Apr 9;4(1):e000647. doi: 10.1136/rmdopen-2018-000647. eCollection 2018.

16.

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.

Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, Hall J, Liu S, Shen Z, Gillen M, Hernandez-Illas M.

RMD Open. 2018 Feb 8;4(1):e000584. doi: 10.1136/rmdopen-2017-000584. eCollection 2018.

17.

Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.

Lee CA, Yang C, Shah V, Shen Z, Wilson DM, Ostertag TM, Girardet JL, Hall J, Gillen M.

Drug Metab Dispos. 2018 May;46(5):532-541. doi: 10.1124/dmd.117.078220. Epub 2018 Feb 28.

PMID:
29490903
18.

Do Financial Constraints Affect Depressive Symptomatology Among Mid-Aged and Older Adults?

Gillen M, Zurlo KA, Kim H.

Int J Aging Hum Dev. 2017 Dec;85(4):438-455. doi: 10.1177/0091415017697724. Epub 2017 Mar 15.

PMID:
29098890
19.

Does "body talk" improve body satisfaction among same-sex couples?

Markey CH, Gillen MM, August KJ, Markey PM, Nave CS.

Body Image. 2017 Dec;23:103-108. doi: 10.1016/j.bodyim.2017.08.004. Epub 2017 Sep 19.

PMID:
28938226
20.

Body appreciation, anxiety, and depression among a racially diverse sample of women.

Ramseyer Winter V, Gillen MM, Cahill L, Jones A, Ward M.

J Health Psychol. 2019 Sep;24(11):1517-1525. doi: 10.1177/1359105317728575. Epub 2017 Sep 7.

PMID:
28882074
21.

Body appreciation, interest in cosmetic enhancements, and need for uniqueness among U.S. college students.

Gillen MM, Dunaev J.

Body Image. 2017 Sep;22:136-143. doi: 10.1016/j.bodyim.2017.06.008. Epub 2017 Jul 28.

PMID:
28759771
22.

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.

Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, Hall JW.

Drug Des Devel Ther. 2017 Jul 7;11:2077-2086. doi: 10.2147/DDDT.S140658. eCollection 2017.

23.

Beauty and the burn: tanning and other appearance-altering attitudes and behaviors.

Gillen MM, Markey CH.

Psychol Health Med. 2017 Dec;22(10):1271-1277. doi: 10.1080/13548506.2017.1330544. Epub 2017 May 24.

PMID:
28537192
24.

Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.

Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Kerr B.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):377-387. doi: 10.1002/cpdd.323. Epub 2017 Jan 11.

PMID:
28074640
25.

Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide.

Gillen M, Yang C, Wilson D, Valdez S, Lee C, Kerr B, Shen Z.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):363-376. doi: 10.1002/cpdd.324. Epub 2017 Jan 9.

PMID:
28067999
26.

Associations Between Body Appreciation and Comfort Communicating About Sex: A Brief Report.

Ramseyer Winter V, Gillen MM, Kennedy AK.

Health Commun. 2018 Mar;33(3):359-362. doi: 10.1080/10410236.2016.1255845. Epub 2016 Dec 29.

PMID:
28033473
27.

Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.

Flanagan T, Martin P, Gillen M, Mathews D, Lisbon E, Kruusmägi M.

Eur J Clin Pharmacol. 2017 Feb;73(2):185-195. doi: 10.1007/s00228-016-2156-4. Epub 2016 Nov 17.

PMID:
27858108
28.

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.

Gillen M, Valdez S, Zhou D, Kerr B, Lee CA, Shen Z.

Drug Des Devel Ther. 2016 Nov 1;10:3555-3562. eCollection 2016.

29.

Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.

Shen Z, Gillen M, Tieu K, Nguyen M, Harmon E, Wilson DM, Kerr B, Lee CA.

Drug Des Devel Ther. 2016 Oct 27;10:3509-3517. eCollection 2016.

30.

Effects of receipt of Social Security retirement benefits on older women's employment.

Gillen M, Heath CJ.

J Women Aging. 2017;29(5):448-459. doi: 10.1080/08952841.2016.1214035. Epub 2016 Sep 14.

PMID:
27629359
31.

An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.

Grime K, Pehrson R, Nordell P, Gillen M, Kühn W, Mant T, Brännström M, Svanberg P, Jones B, Brealey C.

Br J Clin Pharmacol. 2017 Feb;83(2):381-392. doi: 10.1111/bcp.13102. Epub 2016 Oct 13.

32.

Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Gomez-Quiroz LE, Seo D, Lee YH, Kitade M, Gaiser T, Gillen M, Lee SB, Gutierrez-Ruiz MC, Conner EA, Factor VM, Thorgeirsson SS, Marquardt JU.

Toxicology. 2016 Jun 15;361-362:39-48. doi: 10.1016/j.tox.2016.07.004. Epub 2016 Jul 6.

33.

Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.

Martin P, Gillen M, Millson D, Oliver S, Brealey C, Surry D, Sweeny D, Lau D, Leese P.

Clin Pharmacol Drug Dev. 2016 May;5(3):170-9. doi: 10.1002/cpdd.243. Epub 2016 Mar 23.

PMID:
27163495
34.

In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters.

Shen Z, Yeh LT, Wallach K, Zhu N, Kerr B, Gillen M.

Clin Drug Investig. 2016 Jun;36(6):443-52. doi: 10.1007/s40261-016-0386-y.

35.

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.

Martin P, Gillen M, Ritter J, Mathews D, Brealey C, Surry D, Oliver S, Holmes V, Severin P, Elsby R.

Drugs R D. 2016 Mar;16(1):93-107. doi: 10.1007/s40268-015-0120-x.

36.

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.

Martin P, Gillen M, Millson D, Oliver S, Brealey C, Grossbard EB, Baluom M, Lau D, Sweeny D, Mant T, Craven K.

Drugs R D. 2016 Mar;16(1):81-92. doi: 10.1007/s40268-015-0118-4.

37.

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.

Martin P, Oliver S, Gillen M, Marbury T, Millson D.

Clin Ther. 2015 Dec 1;37(12):2823-36. doi: 10.1016/j.clinthera.2015.09.016. Epub 2015 Oct 27.

PMID:
26519231
38.

Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.

Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, Baluom M, Lau D, Mant T.

Clin Ther. 2015 Dec 1;37(12):2811-22. doi: 10.1016/j.clinthera.2015.09.018. Epub 2015 Oct 26.

PMID:
26514315
39.
40.

Sex Rules: Emerging Adults' Perceptions of Gender's Impact on Sexuality.

Maas MK, Shearer CL, Gillen MM, Lefkowitz ES.

Sex Cult. 2015 Dec 1;19(4):617-636. Epub 2015 Apr 9.

41.

Revisiting Pneumatic Nail Gun Trigger Recommendations.

Albers J, Lowe B, Lipscomb H, Hudock S, Dement J, Evanoff B, Fullen M, Gillen M, Kaskutas V, Nolan J, Patterson D, Platner J, Pompeii L, Schoenfisch A.

Prof Saf. 2015 Mar;60(4):30-33.

42.

Psychosocial work factors in new or recurrent injuries among hospital workers: a prospective study.

Lee SJ, You D, Gillen M, Blanc PD.

Int Arch Occup Environ Health. 2015 Nov;88(8):1141-8. doi: 10.1007/s00420-015-1038-x. Epub 2015 Mar 12.

43.

Associations between positive body image and indicators of men's and women's mental and physical health.

Gillen MM.

Body Image. 2015 Mar;13:67-74. doi: 10.1016/j.bodyim.2015.01.002. Epub 2015 Feb 12.

PMID:
25682474
44.

How Gendered Attitudes Relate to Women's and Men's Sexual Behaviors and Beliefs.

Lefkowitz ES, Shearer CL, Gillen MM, Espinosa-Hernandez G.

Sex Cult. 2014 Mar;18(4):833-846.

45.

Work-related violence experienced by urban taxi drivers.

Burgel BJ, Gillen M, White MC.

Am J Ind Med. 2014 Dec;57(12):1377-85. doi: 10.1002/ajim.22397. Epub 2014 Oct 20.

PMID:
25331679
46.

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects.

Gummesson A, Li H, Gillen M, Xu J, Niazi M, Hirshberg B.

Clin Drug Investig. 2014 Nov;34(11):763-72. doi: 10.1007/s40261-014-0230-1.

PMID:
25269885
47.

Body image and HIV risk among college students.

Gillen MM, Markey CN.

Am J Health Behav. 2014 Nov;38(6):816-22. doi: 10.5993/AJHB.38.6.3.

PMID:
25207507
48.

Bronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide.

Berger WE, Gillen M, Eckerwall G, Uryniak T, Trudo FJ, Lampl KL.

Allergy Asthma Proc. 2014 Mar-Apr;35(2):134-40. doi: 10.2500/aap.2014.35.3746.

PMID:
24717790
49.

Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits.

Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, Galle PR, Factor VM, Park YN, Thorgeirsson SS.

J Hepatol. 2014 Feb;60(2):346-353. doi: 10.1016/j.jhep.2013.10.014. Epub 2013 Oct 26.

50.

Epigenetic reprogramming modulates malignant properties of human liver cancer.

Raggi C, Factor VM, Seo D, Holczbauer A, Gillen MC, Marquardt JU, Andersen JB, Durkin M, Thorgeirsson SS.

Hepatology. 2014 Jun;59(6):2251-62. doi: 10.1002/hep.27026. Epub 2014 May 1.

Supplemental Content

Loading ...
Support Center